These multi-pathway regulatory properties not only elucidate GAL’s comprehensive advantages in alleviating liver injury, inflammation, and cholestasis induced by primary biliary cholangitis PBC, but also provide research directions for investigating the molecular mechanism network underlying its therapeutic effects on PBC, while suggesting future optimization of its application potential through multi-target synergistic regulation strategies. This evidence concerns the gene GAL and cholestasis.